According to the company which pioneers imaging biomarkers for precision medicine, QP-Insights enables researchers to leverage clinical imaging data throughout drug development programs.
Quibim says that QP-Insights was designed alongside researchers to provide a comprehensive platform for medical images and other multi-omics including clinical and genetic data to be stored, accessed, and analyzed.
With the growing importance of real-world data (RWD) to inform drug development efforts, the company says a robust platform to extract insights from RWD is critical to unlocking this potential.
Angel Alberich-Bayarri, Co-founder and CEO of Quibim, said: “As a company looking to speed up the early detection of cancer and other diseases, we are acutely aware of the important role that our research, healthcare and pharmaceutical partners play in ensuring the technology actually gets used to treat real-life patients.
“What is so exciting to us about QP-Insights is that it marks a milestone in how we’re able to use already existing clinical data sources from the healthcare sector to further develop our products with predictive functionality, as well as in the ease with which pharmaceutical researchers can use the technology itself in research going forward.”
Researchers will also have access to Quibim’s data processing tools for, among other things, image harmonization and annotation. The company says this is the foundation on which AI-based tools can be built to accelerate the development of precision medicines.
It is being rolled out around the world and carefully designed to comply with all relevant international data privacy and cybersecurity regulations and standards such as the European Union’s General Data Protection Regulation (GDPR), US Health Insurance Portability and Accountability Act (HIPAA) and GAMP, the Good Automated Manufacturing Practice.
In addition to being an all-in-one data processing and management solution, Quibim says QP-Insights will be the platform on which imaging-based biomarker algorithms can be deployed to help researchers stratify and identify individuals most likely to benefit or experience side effects from investigational medicines earlier.
The company has already rolled the platform out and believe it is already tried and trusted by leading biopharmaceutical companies, and it is the backbone for nine EU-wide research consortiums, including the European Federation for Cancer Images (EUCAIM) tasked with helping meet the targets set out in its Europe’s Beating Cancer Plan.
Quibim has also announced several high-profile partnerships in recent months, including Merck KGaA to develop imaging biomarkers models used to predict cancer patient response to immunotherapy and inform decisions in its global drug development efforts.